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Background/purpose: Diabetes mellitus (DM) disproportionately affects Hispanic patients. DM patients have
enhanced platelet reactivity and reduced sensitivity to clopidogrel. Ticagrelor demonstrated a more rapid
onset and greater magnitude of platelet inhibition than clopidogrel in Hispanic patients with stable coronary
artery disease (CAD). This subgroup analysis examined the onset and level of platelet inhibition of ticagrelor
and clopidogrel in Hispanic patients with DM.
Methods/materials: This was a subgroup analysis of a randomized, open-label, crossover study in which 40
Hispanic patients with stable CAD received ticagrelor 180 mg loading dose (LD)/90mg twice-daily maintenance
dose (MD) then clopidogrel 600 mg LD/75 mg once-daily MD, or vice versa. The primary end point was on-
treatment platelet reactivity at 2 hours post-LD using the VerifyNow™ P2Y12 test.
Results: 21 patients hadDMand 19were non-diabetic. At 2 hours post-LD,mean platelet reactivity in the diabetic
groupwas 34.5 PRUwith ticagrelor versus 219.3 PRUwith clopidogrel (P b 0.001), and in the non-diabetic group
was 33.7 PRU with ticagrelor versus 181.0 PRU with clopidogrel (P b 0.001). In both diabetic and non-diabetic
subgroups, mean platelet reactivity declined to a signiﬁcantly greater extent with ticagrelor than clopidogrel at
all time points evaluated (0.5, 2, and 8 hours post LD and after 7–9 days of MD). Patients were signiﬁcantly
more likely to have high on-treatment platelet reactivity (≥208 PRU) during treatment with clopidogrel
compared with ticagrelor, regardless of diabetic status.
Conclusions: Among Hispanic patients with stable CAD, ticagrelor achieves a faster onset and greater magnitude
of platelet inhibition compared with clopidogrel, irrespective of diabetic status.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The prevalence of diabetesmellitus (DM) is expected to continue in-
creasing, with some estimates suggesting that one third of the US adult
population will be affected by diabetes by 2050 [1]. However, the
burden of diabetes is not evenly spread across the US population, with
a disproportionately high prevalence among ethnic minorities, inclu-
ding Hispanics [2,3], and those at the lowest income and educational
levels [4]. Diabetes is the ﬁfth leading cause of death among Hispanic
Americans and, compared with non-Hispanic white adults, the risk of
developing DM is 66% higher among Hispanic/Latino adults [3].
Patients with DM have high platelet reactivity [5–7], which contri-
butes to a high incidence of coronary artery disease (CAD) in theseenter I, 1510 San Pablo Street,
130; fax: +1 323 442 6133.
lavijo).
. This is an open access article underindividuals. Studies show that patients with diabetes have a more
than three-fold higher risk of developing fatal CAD compared with
non-diabetic individuals, which may be associated with the clustering
of cardiovascular risk factors in patients with diabetes [8]. This high-
lights the importance of effective primary and secondary preventive
therapies in diabetic patients to minimize the risk. However, diabetes
may also affect response to treatment. For example, diabetic patients
show a reduced responsiveness to the P2Y12 inhibitor clopidogrel
compared with non-diabetic patients [5], and this reduced responsive-
ness is linked to worse cardiovascular outcomes [9].
Ticagrelor is an orally administered, direct-acting, reversibly binding
P2Y12 receptor antagonist that inhibits adenosine diphosphate (ADP)-
induced platelet aggregation [10,11]. Ticagrelor differs from clopidogrel
in that it is not a prodrug and does not require conversion by hepatic
metabolism to be active [10,12]. Another key difference between the
two agents is that ticagrelor has also been shown to inhibit cellular
uptake of adenosine via inhibition of the equilibrative nucleoside
transporter 1 (ENT1), whereas clopidogrel has not [13].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(75–100 mg/day), to prevent atherothrombotic events in patients with
acute coronary syndrome (ACS) [14], based on its efﬁcacy and safety
over 12 months of follow-up in the large-scale, randomized, phase III
PLATelet inhibition and patients Outcomes (PLATO) trial [15]. A
substudy of the PLATO trial found that ticagrelor reduced the incidence
of ischemic events compared with clopidogrel in patients with DM in a
manner consistent with the results of the overall PLATO cohort. [16]
These data suggest that ticagrelor may be a suitable alternative to
clopidogrel for patients with diabetes.
Wehave previously conducted amulticenter, open-label, randomized,
multiple-dose, crossover study in Hispanic patients with documented
CAD, and found that platelet reactivity was more strongly inhibited by
ticagrelor than clopidogrel [17]. The inclusion of a high proportion of
diabetic patients in this study provided the opportunity to study the
effects of ticagrelor or clopidogrel in Hispanic patients with and without
diabetes. Therefore, the objectives of the current substudy were to
compare on-treatment platelet reactivity during treatment with
ticagrelor versus clopidogrel in Hispanic CAD patients with and without
DM, and to assess the safety proﬁle of ticagrelor in this patient group.
2. Materials and methods
This was a subgroup analysis of a randomized, open-label, crossover
study conducted at 6 US centers between April 2012 and May 2013
(clinicaltrials.gov identiﬁer, NCT01523366). The complete methods
have been published previously [17]. Brieﬂy, the study included adults
aged ≥18 years, who self-identiﬁed as Hispanic, had documented stable
CAD based on having stable angina pectoris, or a history of MI, or revas-
cularization, and were receiving aspirin 75–100 mg/day. The diabetic
status of each patient was assessed at randomization. Patients with
DM were eligible for enrolment if they had a glycosylated hemoglobin
(HbA1c) level of b10%. Patients at increased risk of bleeding were ex-
cluded from the study, as were patients who had any indication for
oral anticoagulant or dual antiplatelet therapy, and those taking strong
cytochrome P450 (CYP) 3A4 inhibitors or inducers. Other exclusion
criteria have been described in detail previously [17].
The study was approved by the Institutional Review Boards at all
sites, and conducted in accordance with the provisions of the Declara-
tion of Helsinki and AstraZeneca policy on bioethics. All patients provi-
ded written informed consent prior to study entry.
Patients were randomized 1:1 to receive open-label treatment in
two possible sequences: clopidogrel ﬁrst and ticagrelor second, or vice
versa, each for 7–9 days, separated by a 10- to 14-day washout period
(Fig. 1). During each active treatment period, patients received a single
loading dose (LD) followed by maintenance dosing (MD) for 7–9 days,
in addition to their usual daily aspirin dose of 75–100 mg. ClopidogrelFig. 1. Study design. Taken from J Thromb Thrombolysis 2015;39:8doses were 600 mg for LD and 75 mg once daily for MD; ticagrelor
doses were 180 mg for LD and 90 mg twice daily for MD.
Each patient made eight visits to the study center during the 11-
week study. Screening was conducted at visit 1 and randomization at
visit 2, then three visits occurred during each treatment period, and
one follow-up visit at 7–10 days after the ﬁnal treatment visit.
Blood samples were taken for analysis of platelet reactivity at base-
line prior to LD, and at 0.5, 2, and 8 hours after the LD. In addition, sam-
ples were taken just prior to, and 2 and 8 hours after the last morning
dose of both agents, as well as 12 hours after the last evening dose of
ticagrelor and 24 hours after the last morning dose of clopidogrel.
During the ticagrelor treatment period, blood samples were drawn at
the same time as the platelet reactivity samples, to measure plasma
concentrations of ticagrelor and its active metabolite AR-C124910XX.
Platelet reactivity was assessed using the VerifyNow® P2Y12 test
(Accumetrics, San Diego, CA), a validated measure of ADP-induced
platelet aggregation [18,19]. In this assay, P2Y12-mediated reactivity is
expressed in P2Y12 reaction units (PRU), with higher values reﬂecting
greater reactivity. Study personnel were blinded to the PRU results.
The primary endpoint of the substudywas the inhibition of platelet re-
activity with ticagrelor versus clopidogrel 2 hours after LD, by DM status.
Secondary end points included the PRU at other time points by DM status,
and the safety of ticagrelor inHispanic patientswith versuswithout diabe-
tes. Safety and tolerability were assessed by the incidence and severity of
adverse events, and by assessment of clinical laboratory parameters, phy-
sical examination, 12-lead electrocardiograph (ECG) and vital signs.
2.1. Statistical analysis
A pretrial estimate showed that a sample size of 12 patients would
provide 90% power to detect a difference of 100 PRUs in the primary
end point between ticagrelor and clopidogrel, assuming a standard de-
viation (SD) of 93 PRU, a correlation of 0.5 between paired observations
and a 2-sided alpha level of 0.05. However, it was planned that 34 pa-
tients would be enrolled to ensure 28 evaluable patients, which would
provide N99% power to detect the anticipated primary outcome effect.
This sample size would also provide sufﬁcient power to evaluate
P2Y12 inhibition at secondary time points, within the subgroups of
patients with versus without diabetes, and provide a larger sample
size for analysis of potential adverse events.
Categorical variables were reported as counts and percentages, and
continuous variables as mean ± SD. The primary end point, PRU analy-
sis, was undertaken using a mixed-effect model with terms for treat-
ment period, treatment sequence and a random effect for patient
within sequence. Mean on-treatment reactivity was estimated using
least squares means and 2-sided 95% conﬁdence intervals (CIs). Data
were analyzed in each group of patients with versus without diabetes–14 [17](with permission). BID, twice daily; QD, once daily.
Fig. 2. Platelet reactivity expressed in P2Y12 reaction units (PRU) at each measured time
point after ticagrelor or clopidogrel in diabetic patients and non-diabetic patients. The
left-hand panel presents PRU post-loading dose (LD) and the right-hand panel presents
PRU following the last morning dose after 7–9 days of ticagrelor 90mg BID or clopidogrel
75mg OD. **P b 0.05, ***P b 0.001 versus clopidogrel at 30-minute time point. Values con-
nected by solid or dotted lines are the least-squares mean and 95% conﬁdence interval
from mixed effect models at each time point. The individual values plotted at baseline
(BL) are the observed mean and 95% CI for the mean, and were not obtained from the
models that the other estimates are based upon. Patients with low BL PRU values (indicat-
ing an incomplete washout from anti-platelet therapy) are excluded during the period
corresponding to the low BL value.
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evaluate the percentage of patients with high on-treatment platelet
reactivity (deﬁned as ≥208 PRU, according to recent expert consensus
recommendations) [20] in the ticagrelor versus clopidogrel groups, at
all time points, and this comparison used Fisher’s exact test.
Pharmacodynamic assessments were undertaken on all patients
who had valid PRU data available and no major protocol violations,
and safety assessments were undertaken on all patients who received
at least one dose of study medication. Safety was evaluated using
descriptive statistics.
3. Results
Of the 40 patients who were randomized to treatment, 38 patients
received both ticagrelor and clopidogrel, and completed the study.
One patient randomized to receive ticagrelor withdrew consent and
discontinued the study during ticagrelor treatment. In addition, one pa-
tient successfully completed ticagrelor treatment and crossed over to
clopidogrel, but did not complete clopidogrel treatment. Of the 40 ran-
domized patients, 21 patients (52.5%) had Type 2 DM and 19 (47.5%)
were non-diabetic. Demographic and clinical characteristics are shown
in Table 1. The diabetic subgroup included more females (42.9%) com-
pared with the non-diabetic subgroup (15.8%). Patients without diabe-
tes were slightly older than diabetic patients (mean ± SD: 65.7 ±
8.1 years in non-diabetic patients versus 62.0± 9.3 years in diabetic pa-
tients), and had a lower bodyweight (mean: 77.8: ± 12.9 kg) and BMI
(median: 28.8 kg/m2) compared with the diabetic subgroup (mean
weight: 87.9 ± 17.6 kg and median BMI: 30.5 kg/m2).
In the diabetic subgroup, baselinemean± SD platelet reactivity was
282.7 ± 58.8 PRU before ticagrelor, and 298.5 ± 50.1 PRU before
clopidogrel. Baseline platelet reactivity was a little lower in the non-
diabetic subgroup: mean ± SD 260.7 ± 74.9 PRU before ticagrelor and
258.3 ± 61.6 PRU before clopidogrel. Analysis of platelet inhibition
over time showed that ticagrelor provided a faster onset and greater ex-
tent of platelet inhibition compared with clopidogrel, regardless of dia-
betic status (Fig. 2). At 2 hours post-LD, ticagrelor treatment was
associated with signiﬁcantly lower platelet reactivity compared with
clopidogrel treatment in diabetic patients (mean: 34.5 ± 33.5 PRUTable 1
Baseline demographics and clinical characteristics in the diabetic and non-diabetic cohorts
of Hispanic CAD patients.
Diabetic
subgroup (n = 21)
Non-diabetic
subgroup (n = 19)
Ethnicity, n (%)
Hispanic or Latino 21 (100.0) 19 (100.0)
Diabetes, n (%)
Diabetes mellitus Type I – –
Diabetes mellitus Type II 21 (100.0) –
Mean (SD) age, years 62.0 (9.3) 65.7 (8.1)
Age ≥65 years, n (%) 8 (38.1) 10 (52.6)
Gender, n (%)
Male 12 (57.1) 16 (84.2)
Female 9 (42.9) 3 (15.8)
Mean weight (SD), kg 87.9 (17.6) 77.8 (12.9)
Median (range) BMI, kg/m2 30.5 (25.2–42.9) 28.8 (20.4–39.7)
Obesity (BMI N30 kg/m2), n (%) 11 (52.4) 6 (33.3)
Cardiovascular risk factors, n (%)
Hypertension 20 (95.2) 18 (94.7)
Dyslipidemia* 20 (95.2) 19 (100.0)
Medical history, n (%)
Previous MI 12 (57.1) 14 (73.7)
Previous PCI 17 (81.0) 15 (78.9)
CABG 7 (33.3) 6 (31.6)
Stable angina pectoris 6 (28.6) 2 (10.5)
Congestive heart failure 1 (4.8) 2 (10.5)
Renal disease 0 (0) 1 (5.3)
*Including hypercholesterolemia.
BMI, body mass index; CABG, coronary artery bypass graft; MI, myocardial infarction; PCI,
percutaneous coronary intervention; SD, standard deviation.with ticagrelor versus 219.3 ± 84.3 PRU with clopidogrel, P b 0.001)
and in non-diabetic patients (mean: 33.7 ± 30.4 with ticagrelor versus
181.0 ± 89.2 PRU with clopidogrel, P b 0.001). There was no signiﬁcant
interaction between the treatment effect and diabetes status (P=0.13).
At all time points evaluated, ticagrelor treatment lowered platelet reac-
tivity to a signiﬁcantly greater extent than clopidogrel did, in both the
diabetic and non-diabetic subgroups (Fig. 2).
A higher proportion of patients showed high on-treatment platelet
reactivity (≥208 PRU)with clopidogrel thanwith ticagrelor, irrespective
of diabetic status (Fig. 3). At 2 hours after the clopidogrel LD, 66.1% of
the diabetic subgroup and 37.5% of the non-diabetic subgroup had a
PRU of ≥208, whereas at 2 hours after the ticagrelor LD, PRU was
b208 in all patients, irrespective of diabetic status.
3.1. Safety and tolerability
Both study treatments were generally well tolerated, and no deaths,
serious adverse events (AEs) or severe AEs were reported after either
ticagrelor or clopidogrel. In addition, no bleeding events were reported
in either group. Eleven patients (27.5%) experienced at least one AE; 7
patients in the diabetic subgroup (33.3%) and 4 in the non-diabetic
subgroup (21.1%). Most AEs were mild in intensity (Table 2), but two
moderate intensity AEs occurred: one case of increased heart rate in a
non-diabetic patient receiving ticagrelor and one case of a fall in a
diabetic patient receiving clopidogrel. No patients discontinued study
medication due to an AE, and no clinically relevant changes in physical
examinations or vital signs were reported during the study.
4. Discussion
According to the 2012 US Census Bureau estimates, almost 17% of
the US population were Hispanic or Latino [21], and this population
group is at particularly high risk of developing Type 2DM [3].Moreover,
the number of cardiovascular risk factors, including DM, tends to be dis-
proportionately higher among Hispanic individuals in the lowest socio-
economic or educational groups, and among those who have lived
longer in the US and are more acculturated to the US way of life [22].
Previous studies have shown that patients with DM have a reduced re-
sponse to clopidogrel treatment [5], so it was important to determine
whether there was an interaction between DM and the antiplatelet
Fig. 3. Percentage of patients with high on-treatment platelet reactivity deﬁned as a
PRU ≥ 208 in (a) diabetic patients, and (b) non-diabetic patients receiving ticagrelor and
clopidogrel. Baseline (BL); P2Y12 reaction units (PRU); Loading dose (LD); Maintenance
dose (MD); P= Fisher’s exact test P value (2-tail) for ticagrelor versus clopidogrel.
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with diabetes.
Our study had previously demonstrated that ticagrelor has a faster
onset and greater extent of platelet inhibition compared with
clopidogrel in Hispanic patients with CAD [22]. The current subgroup
analysis conﬁrmed that this was also the case in Hispanic CAD patients
with or without diabetes. At 2 hours after the LD, patients in both
the diabetic and non-diabetic subgroups showed signiﬁcantly lowerTable 2
Adverse events.












Any adverse event 3 (14.3) 1 (19.0) 2 (10.5) 2 (11.1)
Diarrhea 1 (4.8) 0 (0.0) – –
Upper abdominal pain 0 (0.0) 1 (4.8) – –
Irregular heart rate 1 (4.8) 0 (0.0) – –
Increased heart rate – – 1 (5.3) 0 (0.0)
Oropharyngeal discomfort – – 1 (5.3) 0 (0.0)
Dyspnea 1 (4.8) 0 (0.0) 1 (5.3) 0 (0.0)
Malaise – – 1 (5.3) 0 (0.0)
Headache 1 (4.8) 1 (4.8) 0 (0.0) 1 (5.6)
Dizziness – – 1 (5.3) 0 (0.0)
Dysgeusia – – 1 (5.3) 0 (0.0)
Burning sensation 1 (4.8) 0 (0.0) – –
Fall 0 (0.0) 2 (9.5) – –
Rib fracture 0 (0.0) 1 (4.8) – –
Musculoskeletal chest pain 1 (4.8) 0 (0.0) – -
Nasopharyngitis – – 0 (0.0) 1 (5.6)platelet reactivity after ticagrelor compared with clopidogrel, as mea-
sured by PRU. Similarly, at all on-treatment time points following the
LD, and throughout the maintenance dosing period, platelet reactivity
remained signiﬁcantly lower after ticagrelor than clopidogrel. These
ﬁndings are consistent with previous data from a similar study among
African-American patients with stable CAD [23], and with ﬁndings in a
mixed race population of patients, 88% of whom were Caucasian [24].
The overall study also demonstrated that patients receiving
clopidogrel treatment were signiﬁcantly more likely to show high on-
treatment platelet reactivity (≥208 PRU) compared with patients
receiving ticagrelor [17], and this was also true in the diabetic and
non-diabetic subgroups. A similar lack of high on-treatment platelet re-
activity with ticagrelor has been demonstrated in African Americans
with stable CAD [23].
Although high platelet reactivity has long been shown to be associa-
ted with ischemic events, the link between low on-treatment platelet
reactivity and bleeding is less clear. Tantry et al [20] proposed cut-off
values for both high and low on-treatment platelet reactivity, based
on various platelet function assays, adding further to the hypothesis
that there exists a therapeutic window of optimal on-treatment platelet
reactivity that could potentially play a role in future studies.
The more consistent antiplatelet effect of ticagrelor relative to
clopidogrel among diabetic and non-diabetic patients in the current
study may explain the signiﬁcant improvement in cardiovascular out-
comes seen with ticagrelor in the PLATO study [16]. The analysis of out-
comes among the diabetic and non-diabetic patients in PLATO showed
that ticagrelor reduced the risk of the primary end point (a composite
of cardiovascular death, MI or stroke) by 17% (hazard ratio [HR]: 0.83,
95% CI: 0.74–0.93) in patients without diabetes and by 12% (HR: 0.88,
95% CI: 0.76–1.03) in patients with diabetes, relative to clopidogrel,
and that there was no signiﬁcant increase in overall major bleeding
complications [16]. No signiﬁcant interaction for diabetes status was
noted with respect to the primary composite outcome in the PLATO
study [16], a ﬁnding that has also been demonstrated with the P2Y12
inhibitor prasugrel in diabetic and non-diabetic patients in the Trial to
Assess Improvements in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38
(TRITON-TIMI 38) [25].
A poor response to clopidogrel among DM patients is not related to
glycemic control [26,27], but appears to be the result of reduced circu-
lating levels of the drug’s active metabolite [28–30]. Diabetic patients
with moderate-severe chronic kidney disease also have reduced re-
sponse to clopidogrel and a higher prevalence of on-treatment platelet
reactivity compared with diabetic patients in whom renal function is
normal [31]. Impaired renal function is unlikely to have been the
cause of the low platelet response to clopidogrel in our study, because
renal disease was present in only one patient, who from past medical
history was not diabetic.
The safety proﬁle of ticagrelor was similar and consistent in both the
diabetic and non-diabetic subgroups of Hispanic patients in our study.
The overall safety proﬁle of ticagrelor in the present study was consis-
tent with that seen in other studies in patients with stable CAD, inclu-
ding African-American [23] and mixed race cohorts [24].
Our study is not without limitations. First, treatment was adminis-
tered in an open-label fashion which has the potential to introduce
bias. However, we tried to minimize the potential for bias by using an
objective assessment of platelet function and by blinding study person-
nel to the PRU results. Second, the study included relatively few
patients. However, in order to allow for adequate assessment of sub-
groups, we deliberately enrolled more patients than was needed,
based on the pretrial assessment of the required sample size. In addi-
tion, we tried to minimize the potential for variation by randomizing
patients to different treatment sequences and using each patient as
their own control.
In conclusion, ticagrelor treatment provided a faster onset and
greater extent of platelet inhibition compared with clopidogrel in
454 L.C. Clavijo et al. / Cardiovascular Revascularization Medicine 16 (2015) 450–454Hispanic patients with CAD, irrespective of diabetic status. Ticagrelor
treatment could prove beneﬁcial in Hispanic CAD patients with ACS.
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